The Form 4 filing, a report of an insider's stock transactions, was filed on November 12, 2026. That was also the date of the sale.
Mark Sabag is identified as a company officer. His listed title says to see the remarks, whose text is unavailable here.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-12 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 44,710 |
| Price | $44.14 |
| Total Transaction Value | $1,973,544.11 |
| Insider | |
| Ticker Symbol | TEVA |
| Company | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Insider Name | Sabag Mark |
| Insider Title | See "Remarks" |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 80,760 |
| Position Size Change | 35.63% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 44,710 Teva (TEVA) shares in one transaction. It carries transaction code S, which identifies a sale.
What was the average price of the transaction?
The average price was $44.141 per share, shown as $44.14 when rounded to cents.
How did this transaction affect the insider's holdings?
Mark Sabag reported 80,760 shares owned after the sale. The 44,710 shares sold were 35.63% of his reported shares before the sale.
What's the total transaction value?
The total transaction value was $1,973,544.11 for the 44,710 shares sold in one transaction.
Are there any special circumstances around this transaction?
The sale may be linked to a code M exercise or conversion in the same filing. An exercise can use a stock option, which gives someone the right to buy shares at a set price. A conversion can turn another type of investment into shares.
That link is based on the two steps having the same share count. Details of the related acquisition and filing footnotes are unavailable here. Whether both steps involved the same date, type of stock, account, or exact shares remains unknown.
For research purposes only; not investment advice.